INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on May 23, 2022. The report details a material definitive agreement entered into by INVO Centers, LLC, a wholly owned subsidiary of the registrant.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial data disclosed relates to the terms of a new lease agreement:
- Base Rent: $139,455 annually.
- Rent Escalation: 2.5% annual increase.
- Property Size: 5,165 square feet.
Material Changes
The primary material change reported is the execution of a Lease Agreement (the "Tampa Lease") with 4602 North Armenia Ave, LLC. This agreement secures premises at 4602 North Armenia Avenue, Suite 200, Tampa, FL, to establish a previously announced INVO Center clinic.
Outlook and Management Commentary
Management indicates the lease term is estimated to begin on December 1, 2022, and end on March 31, 2033. The filing does not contain forward-looking guidance regarding revenue, earnings, or other operational outlooks beyond the establishment of this specific clinic location. No risks or contingencies were explicitly detailed in this specific report text.
Investor Verification Checklist
- Verify the operational readiness of the Tampa clinic for the estimated December 1, 2022, commencement date.
- Confirm the total capital expenditure required to fit out the 5,165 square foot space, as this is not disclosed in the filing.
- Review the full text of the Lease Agreement (Exhibit 10.1) for potential termination clauses or additional financial obligations not summarized here.
- Check subsequent filings for updates on the clinic's opening status and impact on the company's cash burn rate.